Financiado en parte por Funds of Capio, Lion's Sweden, Pronova Biocare A/S
Transfer of omega-3 fatty acids across the blood-brain barrier after dietary supplementation with a docosahexaenoic acid-rich omega-3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study
Freund Levi Y, Vedin I, Cederholm T, Basun H, Faxén Irving G, Eriksdotter M, Hjorth E, Schultzberg M, Vessby B, Wahlund LO, Salem N, Palmblad J
Journal of internal medicine · 116 citas
Etiquetas de revisión
Financiado por la industriaSolo mecanismosDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Solo mecanismos
Quién lo pagó
- Financiación
- Financiado por la industria
- Organización sin fines de lucro
- Demensförbundet
- Universidad u hospital
- Karolinska Institutet
- Gobierno
- Stockholms Läns Landsting
- Empresa
- Funds of Capio
- Sin clasificar
- The Regional Agreement on Medical Training and Clinical Research
- Organización sin fines de lucro
- Gamla Tjänarinnor
- Empresa
- Lion's Sweden
- Empresa
- Pronova Biocare A/S
- Organización sin fines de lucro
- Swedish Alzheimer Foundation
- Organización sin fines de lucro
- Gun och Bertil Stohnes Foundation
- Organización sin fines de lucro
- Odd Fellow Sweden
- Organización sin fines de lucro
- Swedish Society of Physicians
- Gobierno
- Stockholm County Council
- Organización sin fines de lucro
- Swedish Nutrition Foundation
- Subvenciones
- Karolinska Institutet (20110263); Karolinska Institutet (20110604)
Según 14 financiadores declarados.
Publicación
- Publicado
- 2013-11-25 · J Intern Med · vol. 275 · número 4 · págs. 428–436
- Editorial
- Wiley
- Citado
- 164 citas · más que el 99% de estudios similares · 10.2× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 39 trabajos
- Acceso
- De pago
- Áreas de investigación
- Fatty Acid Research and Health · Alzheimer's disease research and treatments · Barrier Structure and Function Studies
- Palabras clave
- omega-3 fatty acids, docosahexaenoic acid, blood-brain barrier, cerebrospinal fluid, Alzheimer's disease, dietary supplementation, eicosapentaenoic acid, plasma fatty acids, tau phosphorylation, interleukin-1 receptor type II, neuroinflammation
- MeSH
- blood-brain barrier, humans, alzheimer disease, disease progression, fatty acids, omega-3, docosahexaenoic acids, eicosapentaenoic acid, tau proteins, administration, oral, follow-up studies, double-blind method, phosphorylation, dietary supplements, adult, biomarkers
12 autores
- Yvonne Freund‐Levi🇸🇪Karolinska University Hospital; Karolinska Institutet
- Inger Vedin🇸🇪Karolinska University Hospital; Karolinska Institutet
- Tommy Cederholm🇸🇪Uppsala University Hospital
- Hans Basun🇸🇪Uppsala University Hospital
- Gerd Faxén Irving🇸🇪Karolinska University Hospital; Karolinska Institutet
- Maria Eriksdotter🇸🇪Karolinska University Hospital; Karolinska Institutet
- Erik Hjorth🇸🇪Karolinska University Hospital; Karolinska Institutet
- Marianne Schultzberg🇸🇪Karolinska University Hospital; Karolinska Institutet
- B. Vessby🇸🇪Uppsala University Hospital
- Lars‐Olof Wahlund🇸🇪Karolinska University Hospital; Karolinska Institutet
- N. Salem🇺🇸National Institutes of Health; National Institute on Alcohol Abuse and Alcoholism
- Jan E.W. Palmblad🇸🇪 · autor de correspondenciaKarolinska University Hospital; Karolinska Institutet
Resumen
El texto original del estudio, en el idioma en que se publicó.
Objective
Little is known about the transfer of essential fatty acids (FAs) across the human blood-brain barrier (BBB) in adulthood. In this study, we investigated whether oral supplementation with omega-3 (n-3) FAs would change the FA profile of the cerebrospinal fluid (CSF).
Methods
A total of 33 patients (18 receiving the n-3 FA supplement and 15 receiving placebo) were included in the study. These patients were participants in the double-blind, placebo-controlled randomized OmegAD study in which 204 patients with mild Alzheimer's disease (AD) received 2.3 g n-3 FA [high in docosahexaenoic acid (DHA)] or placebo daily for 6 months. CSF FA levels were related to changes in plasma FA and to CSF biomarkers of AD and inflammation.
Results
At 6 months, the n-3 FA supplement group displayed significant increases in CSF (and plasma) eicosapentaenoic acid (EPA), DHA and total n-3 FA levels (P < 0.01), whereas no changes were observed in the placebo group. Changes in CSF and plasma levels of EPA and n-3 docosapentaenoic acid were strongly correlated, in contrast to those of DHA. Changes in DHA levels in CSF were inversely correlated with CSF levels of total and phosphorylated tau, and directly correlated with soluble interleukin-1 receptor type II. Thus, the more DHA increased in CSF, the greater the change in CSF AD/inflammatory biomarkers.
Conclusions
Oral supplementation with n-3 FAs conferred changes in the n-3 FA profile in CSF, suggesting transfer of these FAs across the BBB in adults.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.